TB Alliance CEO On Less Toxic Treatment Regimens, Pretomanid Plans

 
• By Anju Ghangurde

TB Alliance CEO Mel Spigelman discusses a range of new and evolving aspects pertaining to the three-drug BPaL regimen for highly drug-resistant TB, including the ZeNix trial results and adding a licensee for pretomanid. He also notes how COVID-19 has had a “terrible impact” on efforts to tackle the TB pandemic.

TB
Efforts To Make TB Treatment Less Toxic • Source: Alamy

More from R&D

More from Scrip